Advances in the clinical value of tissue inhibitors of metalloproteinase-2 and insulin-like growth factor binding protein 7 in sepsis associated-acute kidney injury / 中华危重病急救医学

Sepsis is an important cause of acute kidney injury (AKI). About 60% of sepsis patients will develop AKI. At present, the standard of clinical diagnosis of AKI is still based on the changes in serum creatinine and urine volume. Because of its lag in time, it may lead to delay in treatment and increase the mortality. To find a new biomarker similar to "troponin" for the diagnosis of AKI, and to achieve the early diagnosis and prevention of AKI, is of great significance to reduce the mortality of AKI. In recent years, it has been found that tissue inhibitors of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) can be used for early diagnosis of sepsis associated-acute kidney injury (SA-AKI). They also have important values in risk stratification, prognosis judgment, intervention and other aspects of SA-AKI. In this paper, the research progress of the application of TIMP-2 and IGFBP7 in SA-AKI is reviewed.

Pteridic acid hydrate and pteridic acid C produced by StreStreptomyces pseudoverticillus YN17707 induce cell cycle arrest / 中国天然药物

The present study aimed at identifying cell cycle inhibitors from the fermentation broth of Streptomyces pseudoverticillus YN17707. Activity-guided isolation was performed on tsFT210 cells. Compounds were isolated through various chromatographic methods and elucidated by spectroscopic analyses. Flow cytometry was used to evaluate the cell cycle inhibitory activities of the fractions and compounds. Two compounds were obtained and identified as pteridic acid hydrate (1) and pteridic acid C (2), which arrested the tsFT210 cells at the G0/G1 phase with the MIC values being 32.8 and 68.9 μmol·L(-1), respectively. These results provide a basis for future development of Compounds 1 and 2 as novel cell cycle inhibitors for cancer therapy.

A study on new cell-cycle inhibitors from the metabolites of marine-derived Streptomyces flavorectus / 中国海洋药物

Aim To explore the antitumor active metabolites of marine-derived Streptomyces flavorectus Z4-007. Methods The separation procedure was guided by a flow cytometric bioassay using tsFT210 cells to examine cell cycle inhibitory activity, and various column chromatography using silica gel, Sephadex LH-20, and ODS were employed for the isolation and purification of bioactive compounds. Chemical structures were investigated by spectroscopic methods and biological activities were evaluated by flow cytometry using mouse cancer tsFT210 cells. Results Four bioactive compounds were isolated from the fermentation broth of Streptomyces flavorectus Z4-007, one of them had been identified as 1-(2,4-Dihydroxy-3,5-dimethyl-phenyl)-hexa- (E,E)-2,4-dien-1-one (1) and the other three compounds were considered to be peptide, Compound Ⅰ inhibited the cell-cycle of tsFT210 cells at the G_0/G_1 phase at higher concentrations, while at the lower concentrations compound Ⅰ inhibited the cell-cycle mainly at the G_2/M phase, accompanied with induction of apoptosis in the tsFT210 cells.Conclusion Compound Ⅰ was isolated from the metabolites of the genus Streptomyces for the first time and provided as a new cell-cycle inhibitor.